Sunshine Nuohe announced that the company and Jiangsu Wangao Pharmaceutical Co., Ltd. signed the “ABA001 Project Cooperation and Development Agreement” to jointly develop ABA001, a new class 1 chemical drug for high blood pressure. The project is currently in phase I clinical trials. According to the agreement, Wangao Pharmaceutical will invest 50 million yuan in this phase, and the funds will only be used for expenses directly related to clinical trials, R&D and optimization projects within the agreed product; Wangao Pharmaceutical enjoys exclusive commercialization rights and corresponding revenue rights within China, and overseas rights are distributed by both parties according to the actual investment ratio. This cooperation does not constitute a related transaction or major asset restructuring, and is expected to have a positive impact on the company's future performance. There is uncertainty about innovative drug development and post-marketing sales. Milestone payments must meet agreed conditions, and there is uncertainty about the final amount.

Sunshine Nuohe announced that the company and Jiangsu Wangao Pharmaceutical Co., Ltd. signed the “ABA001 Project Cooperation and Development Agreement” to jointly develop ABA001, a new class 1 chemical drug for high blood pressure. The project is currently in phase I clinical trials. According to the agreement, Wangao Pharmaceutical will invest 50 million yuan in this phase, and the funds will only be used for expenses directly related to clinical trials, R&D and optimization projects within the agreed product; Wangao Pharmaceutical enjoys exclusive commercialization rights and corresponding revenue rights within China, and overseas rights are distributed by both parties according to the actual investment ratio. This cooperation does not constitute a related transaction or major asset restructuring, and is expected to have a positive impact on the company's future performance. There is uncertainty about innovative drug development and post-marketing sales. Milestone payments must meet agreed conditions, and there is uncertainty about the final amount.